REG - Venture Life Group - Acquisition of FemiClear and CUROXEN

Venture LifeAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260603:nRSC7361Ga&default-theme=true

RNS Number : 7361G  Venture Life Group PLC  03 June 2026

THIS ANNOUNCEMENT WAS DEEMED BY THE COMPANY TO CONTAIN INSIDE INFORMATION AS
STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS
PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.
WITH THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INFORMATION IS NOW CONSIDERED
TO BE IN THE PUBLIC DOMAIN.

 

3 June 2026

 

 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

 

Acquisition of FemiClear and CUROXEN

 

Venture Life (AIM: VLG), a recognised leader in proactive longevity, health
innovation and global commercialisation within the consumer healthcare sector,
is pleased to announce the acquisition of FemiClear (https://femiclear.com/) ,
and CUROXEN
(https://www.curoxen.com/?_gl=1%2Aau9ikc%2A_ga%2ANzE0NTIwMzQzLjE3ODAzMTEyMjY.%2A_up%2AMQ..%2A_ga_4BGS2V4SLK%2AczE3ODAzMTEyMjUkbzEkZzAkdDE3ODAzMTEyMjUkajYwJGwwJGgw)
(together with FemiClear, the "Brands"), from OrganiCare Nature's Sciences,
LLC ("OrganiCare") for a total consideration of up to $28.0 million (the
"Acquisition").

 

Background to the Brands

Founded in 2016 and based in Austin, Texas, OrganiCare focuses on providing
natural, clinically effective alternatives to synthetic pharmaceuticals, with
its patented technologies being central to both Brands.

 

·      FemiClear, addresses a range of common gynaecological conditions,
including bacterial vaginosis, genital herpes, thrush and urinary tract
infections, while also supporting broader vaginal health.

 

·      CUROXEN, provides infection prevention solutions for wounds and
mouth sores.

 

The Brands have built a strong presence in the US, with distribution across
major retailers, pharmacies and online channels, including Walmart, Walgreens,
CVS and Target, and have delivered a net revenue CAGR of 22.5% over the last
two financial years, with FemiClear representing approximately 98% of the
financial performance.

 

For the 12-month period ended 31 March 2026 (the "Period"), the Brands
generated combined net revenues¹ of approximately $12.1 million, an increase
of 29.1% over the 12-month period ended 31 March 2025 (the "Prior Period"). In
the Period, the Brands also generated gross profit of $7.5 million (Prior
Period: $5.7 million) and contribution² of $3.6 million (Prior Period: $2.8
million).

 

This growth has been delivered through significant confirmed new gains in
distribution over the last twelve months, including the launch in Target and
range expansion in other retailers, resulting in particularly strong
performance in the final quarter of the Period which delivered 39.7% net
revenue improvement over the equivalent quarter in the Prior Period. The
Acquisition is expected to have a working capital impact equating to c.13% of
its last twelve months net revenues, reflecting the investment support behind
the Brands.

 

Strategic rationale

The Board considers the Acquisition to be perfectly aligned with the Group's
strategy and significantly strengthens Venture Life's position within Women's
Intimate Health by:

 

·      Establishing immediate scale and presence in the US market,

·      Expanding access into additional gynaecological treatment
categories,

·      Complementing the Group's existing Balance Activ brand with
significant adjacencies,

·      Providing a meaningful and compelling entry into a $0.7bn USA
Feminine Treatment retail opportunity(3).

 

The Brands have continued to maintain strong trading momentum, with
significant further growth coming from confirmed new listings that are
confirmed to launch throughout 2026, including the launch in Target and range
expansion in other retailers.

 

The Board therefore expects to unlock meaningful synergies at both a revenue
and operating level, including:

 

·      Leveraging extensive distribution relationships to accelerate
growth of the other VLG brands in the US;

 

·      Cross utilisation of expertise and product development
capabilities; and

 

·      Efficiency gains across operations and technology

 

It is anticipated that these benefits will materialise progressively from
calendar year 2027 onwards.

 

Integration and transition

As part of the Acquisition, five employees and one contractor from across the
key commercial and operational functions will join Venture Life to lead the
commercial growth of the Brands and support the entry of other Venture Life
brands into the USA. In addition, the CEO and co-founder of OrganiCare,
Caroline Goodner, will continue to support the Brands and Venture Life for a
transitionary period as a consultant.

 

On completion, Venture Life will enter into a manufacturing agreement for an
initial term of 18 months whereby OrganiCare will continue to provide
manufacturing services to the Brands to facilitate the transition to a
longer-term third-party contract manufacturing organisation, with this initial
term extendable as required until successful production transfer has been
achieved. In addition, as part of the Acquisition, Venture Life and OrganiCare
will enter into a transitional services agreement ("TSA") to ensure a smooth
operational transition.

 

Acquisition terms

On 2 June 2026, the Company entered into a sales and purchase agreement
("SPA") with OrganiCare to acquire the assets associated with the FemiClear
and CUROXEN brands. This includes all intellectual property developed by
OrganiCare including, but not limited to, all of the trademarks plus the
patents relating to manufacturing.

 

Pursuant to the terms of the SPA, the total consideration payable by the
Company to OrganiCare will be up to $28.0 million, with the price including
finished goods inventories and adjusted for an average level of net working
capital.

 

The total consideration comprises:

 

·      an initial consideration of $23.0 million, payable in cash on
completion of the Acquisition;

 

·      up to $4.0 million of deferred consideration payable in cash,
contingent upon the Brands achieving expected trading results for the 12-month
period ending 31 December 2026; and

 

·      up to an additional $1.0 million of deferred consideration
payable in cash, contingent upon the Brands significantly outperforming
expected trading results for the 12-month period ending 31 December 2026.

 

All consideration payable pursuant to the Acquisition will be funded from the
Company's existing cash resources. The total consideration payable equates to
1.9x of net revenue expected to be generated for the 12-month period ending 31
December 2026 and 6.1x of contribution for the same period.

 

Jerry Randall, CEO of Venture Life Group plc commented: "I am delighted to
announce the successful completion of the acquisition of the FemiClear and
Curoxen brands. The Brands are highly complementary to VLG's current women's
intimate health portfolio, are margin enhancing to the Group, and hold a
strong and rapidly growing market position in the US. The Brands are currently
in strong growth with significant confirmed new listings landing through the
course of Q2 to Q4 2026, which will fully impact in 2027. I must compliment
the co-founder, Caroline Goodner, for the tremendous brands and business she
and her team have built, and I am delighted that Caroline will continue to
support the Brands and VLG through the transitionary period with her extensive
expertise and knowledge.

 

The Acquisition brings relationships with key strategic US retailers, a
valuable IP set, and a high calibre team that have been instrumental in the
success of the brands to date, providing an essential, scalable platform for
growth in the US market and women's intimate health category. We expect to
leverage this scalable platform to drive meaningful synergies through
launching and growing existing VLG brands in the US and through cross
pollination of expertise and intellectual property within our women's intimate
health portfolio. This is an excellent use of some of the funds we secured
through the divestments made during 2025, and we still retain meaningful
firepower for further such deals."

 

Caroline Goodner, co-founder of OrganiCare commented: "We are thrilled to be
joining forces with Venture Life Group. They share our commitment to advancing
women's health and recognize the strength of the FemiClear and CUROXEN brands.
FemiClear was created to bring better efficacy through innovative science to
common, recurring women's health concerns such as bacterial vaginosis, yeast
infections, and UTIs, and we believe this transaction will expand these
trusted solutions to a broader audience. With VLG's greater scale, resources,
and other feminine health assets, we are excited for the opportunity to
accelerate growth, expand their U.S. footprint, and continue improving women's
lives."

 

The person responsible for the release of this announcement on behalf of VLG
is Daniel Wells, Chief Financial Officer.

 

Notes:

1.     Net revenue defined as gross revenue less discounts, rebates and
other deductions for damages / returns

2.     Contribution defined as net revenue less cost of goods sold,
adjusted for the established manufacturing supply agreement between Venture
Life and OrganiCare, and distribution, advertising and promotion expenses

3.     US feminine treatment retail extended all outlet combined (xAOC)
sourced from Nielsen IQ

 

For further information, please contact:

 

 Venture Life Group PLC                                    +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)      +44 (0) 20 7220 0500
 Stephen Keys / George Lawson (Corporate Finance)

 Michael Johnson (Sales)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is a consumer self-care company focused on the specific market
opportunity of Proactive Healthy Longevity. The company has a core portfolio,
its Power Brands, of high growth, high margin products that promote and
support consumer's goals of maintaining health and longevity. The Power Brands
include Balance Activ in women's intimate healthcare, Earol® supporting ENT
care, Lift and Glucogel product ranges for energy and glucose management and
hypoglycaemia, and the Health and Her product range supporting the hormonal
lifecycle.

 

These products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels. Venture Life has direct
distribution in the UK, Ireland and the USA, supplying produces directly to
retailer partners. Outside of these territories Venture Life uses
international distribution partners to sell its products.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQFFFLLRAIFIIR



            Copyright 2019 Regulatory News Service, all rights reserved